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Abstract
Background: Diagnostic capacity and suboptimal logistics are consistently identified as barriers to timely diagnosis
of cancer, especially lung cancer. Immediate chest X-ray (CXR) reporting for patients referred from general practice
is advocated in the National Optimal Lung Cancer Pathway to improve time to diagnosis of lung cancer and to
reduce inappropriate urgent respiratory medicine referral for suspected cancer (2WW) referrals. The aim of radioX is
to examine the impact of immediate reporting by radiographers of CXRs requested by general practice (GP) on lung
cancer patient pathways.
Methods: A two-way comparative study that will compare the time to diagnosis of lung cancer for patients. Internal
comparison will be made between those who receive an immediate radiographer report of a GP CXR compared to
standard radiographer GP CXR reporting over a 12-month period. External comparison will be made with a similar,
neighbouring hospital trust that does not have radiographer CXR reporting. Primary outcome is the effect on the
speed of the lung cancer pathway (diagnosis of cancer or discharge). Secondary outcomes include the effect of the
pathway on efficiency including the number of repeat CXRs performed in a timely fashion for suspected infection and
the effect of immediate reporting of GP CXRs on patient satisfaction.
Discussion: The radioX trial will examine the hypothesis that immediate reporting of CXRs referred from GP reduces
the time to diagnosis of lung cancer or discharge from the lung cancer pathway.
Trial registration: International Standard Randomised Controlled Trial Number ISRCTN21818068. Registered on 20
June 2017.
Background
Lung cancer is the leading cause of cancer death world-
wide [1]. When compared to other common cancers, the
prognosis for lung cancer is worse [2]. In the United
Kingdom (UK) there has been a recent modest increase
in survival, with 12.6% of patients with lung cancer sur-
viving for 5 years [3], although 30% of patients die
within 90 days of diagnosis [4]. Diagnosis of lung cancer
is often made at a late stage, when prognosis is poor [5],
and several factors are thought to influence this. Symp-
toms suggesting lung cancer are often non-specific until
late in the disease, which results in diagnostic difficulties
in primary care [4, 6, 7]. In an attempt to address this,
recent guidance by the National Institute for Health and
Care Excellence (NICE) has lowered the threshold for
investigation and referral to specialist care for cases of
possible malignancy, including lung cancer (NG12) [8].
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Imaging has become embedded into an increasing
range of patient pathways, with the number of investiga-
tions performed in England doubling in 9 years [9]. Ser-
vice challenges for radiology in the UK are threefold;
sustained increases in activity [9, 10], a chronic shortage
of consultant radiologists [11, 12] and unprecedented
economic restrictions [13]. Recognising the need to im-
prove patient outcomes for cancer, especially lung cancer
which has shown minimal improvement in survival rates
[2, 5], renewed focus is being given to rapid referral and
diagnosis in cases of suspected cancer [6, 8, 14]. These
initiatives will undoubtedly increase the volume of im-
aging investigations performed at a time when diagnostic
capacity is failing to meet current demand [15].
A clinical report of imaging examinations is essential
to guide diagnostic and treatment decisions. Time to a
clinical report can be a serious factor in diagnostic de-
lays [16–18] with recognition that small delays for lung
cancer diagnosis may contribute to higher stage at diag-
nosis [19] and also a deterioration in performance status
that may influence suitability for treatment. In the set-
ting of the lung cancer pathway, delays are often multi-
factorial, but may be contributed to by the time taken to
report a chest X-ray (CXR). This is because the very first
step in the lung cancer pathway is often the identifica-
tion and reporting of a lung mass on a CXR, which
should then trigger a staging computed tomogram (CT).
The use of appropriately trained radiographers to under-
take clinical reporting is not new. Skeletal radiograph
reporting, for example, has become widespread across the
UK [12, 20], and in many departments provides a signifi-
cant contribution to reporting capacity [21, 22]. More re-
cently, reporting radiographers have been trained to
report CXRs [23, 24] and this has been proposed as a
method of minimising CXR reporting times in patients
with suspected lung cancer [25]. There is some limited
evidence to date that has evaluated CXR accuracy rates of
trained reporting radiographers in comparison with radi-
ologists. Reporting radiographers (n = 40) were found to
have high sensitivity (95.4%; 95% CI 94.4–96.3%) and spe-
cificity (95.9%; 95% CI 94.9–96.7%) at an objective, struc-
tured examination of 100 CXRs at the completion of an
accredited training programme [23].
Recent work found poor compliance with sug-
gested optimal diagnostic investigations for lung
cancer, with 23% of patients in England receiving in-
vestigation and results within the recommended
timeframes with significant variation between regions
[26]. This study aims to evaluate the impact of radi-
ographer reporting on the timeliness, accuracy and
quality of CXR reports, as well as the impact on the
overall lung cancer pathway in comparison with ra-
diologists. These parameters have not previously
been studied in lung cancer patients. The current
study could act as a pilot study for a larger, multisite
evaluation if results are positive.
Methods
The aim of the current study is to investigate the impact
of radiographer immediate CXR reporting on the lung
cancer pathway.
Trial design
A two-way comparative study that will compare the time
to diagnosis of lung cancer for patients. Internal com-
parison will be made between those who receive an im-
mediate radiographer report of a GP CXR compared to
standard radiographer GP CXR reporting (Fig. 1). The
intervention group will receive an immediate CXR re-
port and be offered a CT for CXRs suspicious for cancer.
The control group will have the CXR reported no later
than next working day in line with current protocols.
Key protocol elements are summarised in the SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional trials) 2013 Checklist [27] (Additional File 1)
and Figure (Fig. 2).
The diagnostic aspect of the lung cancer pathway at
Homerton University Hospital is relatively streamlined.
To enable comparison with radiology service delivery at
other institutions’ time to diagnosis (immediate and
standard CXR reporting) will be compared with New-
ham University Hospital (Fig. 2). This adjacent hospital
has comparable patient demographics, a similar number
of lung cancer patients per year and is of comparable
size. Newham does not currently have CXR-reporting
radiographers and does not offer a straight-to-CT service
for CXRs suspicious for lung cancer.
Study setting
Research Ethics Committee and Health Research Au-
thority approval was granted on 6 June 2017 (REC 17/
LO/0870; HRA 221968). This study will not directly re-
cruit patients; it is an evaluation of health service deliv-
ery and, as such, no patient consent is required.
Intervention is at an institutional level and institutional
approval has been gained. No additional or different
tests will be performed, and all the reporting practi-
tioners (reporting radiographers and consultant radiolo-
gists) currently report CXRs in clinical practice. The
comparative aspect of the study is the timing, accuracy
and usefulness of the CXR report; immediate compared
to standard care. Patient-identifiable data will not be
available outside of the direct clinical care team, only
anonymised data will be used. Patients will be assigned a
unique study identifier at time of CXR by the clinical
care team. Block randomisation, institutional rather than
patient enrolment and the use of de-identified data is in
line with previous research that has examined the order
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of interpretation between readers [28]. The intervention is
considered to be an alternative, non-inferior form of stand-
ard practice since radiographer reporting of CXRs has
already been implemented in some NHS trusts in the UK.
Radiographer reporting, including CXRs, has been shown
to create additional diagnostic capacity at centres that have
embedded this into the imaging department [21, 22, 29].
However, the published evidence on radiographer reporting
of CXRs is limited. Furthermore, robust methods of evalu-
ating diagnostic reports (including actionability and useful-
ness) of radiographers and radiologists using independent
experts has not previously been attempted.
Clinical assessment will be made by a general prac-
titioner and a referral made to Homerton University
Hospital for a CXR examination following standard and
established referral procedures. The referral for CXR will
be checked by the performing radiographer or super-
vised assistant practitioner to ensure that the referral
meets Ionising Radiation (Medical Exposure) Regula-
tions (IRMER) (2000) requirements and adheres to de-
partmental protocols for a justified referral. Chest X-rays
will be obtained using digital radiography equipment,
and radiation doses will be as low as possible while
maintaining good image quality. Existing departmental
imaging protocols will be followed. The standard X-ray
projection for a chest examination is a single posterior-
anterior (PA) X-ray. The radiographer or assistant prac-
titioner will check all images for diagnostic quality and
a
b
Fig. 1 Intervention and standard patient pathway at Homerton University Hospital and Newham General Hospital (external comparator). GP general
practitioner, CXR chest X-ray, CT computed tomography, RR reporting radiographer, CR consultant radiologist, Other Resp other respiratory disease, sus
CA suspicious for cancer, 2WW urgent respiratory referral for suspected cancer, Routine Resp routine referral to respirator medicine
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record the radiation dose on the Radiology Information
System (RIS) in line with departmental standard ope-
rating procedures. If the radiographer or assistant prac-
titioner performing the CXR identifies a potentially
significant abnormality; for example, lung cancer or
pneumothorax, this will be triaged for an immediate re-
port according to current protocol.
Inclusion and exclusion criteria are presented in
Table 1.
Randomisation
Intervention is at an institutional level; individual pa-
tients will not be randomised. Half-day sessions will be
randomised to intervention or standard practice, using a
randomisation list provided by the study statistician.
This is in line with previous studies that have examined
the timing or order of X-ray reading but where all exam-
inations are requested as part of routine clinical care
and receive reports from the same practitioners [30].
Intervention
The intervention reporting strategy is modelled on the
National Optimal lung cancer pathway developed in
2016 [31]. The intervention strategy aims to streamline
the patient journey through the lung cancer pathway by
providing prompt interpretation of CXRs referred by
general practice (GP) and offering immediate CT when
appropriate.
Chest X-rays included in the intervention arm will be
reported at the time of image acquisition while the pa-
tient is still in the radiology department. Patients who
have a CXR suspicious for cancer will be offered an im-
mediate CT of the chest and upper abdomen.
Control
Current practice in most radiology departments is for
GP examinations to be reported once the patient has left
the department. Considerable variability exists across
England in the time taken to report X-ray examinations
(report turnaround time; RTAT). At Homerton Univer-
sity Hospital, all GP X-rays are reported during the next
reporting session following examination, with a max-
imum RTAT of one working day. Patients who have a
CXR suspicious for cancer are offered an appointment
for a CT of the chest and upper abdomen via the radi-
ology department secretary team, with the results sent
to the referring GP and the cancer referrals office.
Current practice is that if a suspected abnormality is
identified by the radiographer who performs the CXR an
urgent report (reporting radiographer or consultant radi-
ologist) is arranged while the patient is still in the de-
partment. If the findings are suspicious for lung cancer
the patent is offered a CT of the chest and abdomen.
Fig. 2 Schedule of enrolment, interventions and assessments. CXR chest X-ray, CT computed tomography scan, *when required
Table 1 Inclusion and exclusion criteria
Criteria
Inclusion • Referred for a chest X-ray from general practice
• Aged over 16 years
Exclusion • Active diagnosis of lung cancer
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This protocol will continue throughout the study for the
control reporting sessions.
Outcome measures
The primary outcome is to test the impact of radiog-
rapher immediate reporting of GP CXRs, with immedi-
ate CT where appropriate, on time from performance of
the CXR to treatment (with intermediate time points)/
discharge for lung cancer.
Secondary outcome measures include:
 Measurement of the effect on the speed of the lung
cancer pathway:
(i) 6-and 12-month survival (lung cancer and all-cause)
(ii)Number of emergency admissions for lung cancer
(iii)Performance status at time of decision to treat
(iv)Stage at diagnosis of lung cancer
 Measurement of the effect of the pathway on efficiency
including:
(i) The impact of immediate GP CXR reporting on
the number of urgent respiratory cancer (2WW)
referrals
(ii)The accuracy and usefulness of radiographer
CXR reporting in clinical practice
(iii)The cost-effectiveness of radiographer reporting
(iv)The influence of immediate GP CXR reporting,
with immediate CT where appropriate, on the
number of first 2WW appointments with all
radiology results available
 Measurement of the number of repeat CXRs performed
in a timely fashion for suspected infection
 The effect of immediate reporting of GP CXRs on
patient satisfaction
In addition to comparison as per randomisation within
Homerton University Hospital, primary outcomes will
be compared with a neighbouring hospital, Newham
University Hospital.
Components of the chest X-ray reporting pathway
Reporting radiographer chest X-ray report
All reporting radiographers participating in the study
have completed an accredited postgraduate certificate in
adult CXR reporting (experience 1–8 years) and cur-
rently provide CXR reports in clinical practice. All CXRs
referred by GP on eligible patients (aged over 16 years,
no active history of lung cancer) will receive a reporting
radiographer report. In line with current practice, a
narrated report will be provided rather than a structured
report. Image interpretation will occur on Picture
Archiving and Communication System (PACS) worksta-
tions and the report entered into PACS and transferred
to the patient electronic record. If the reporting radiog-
rapher requires additional investigations (repeat X-ray
due to inadequate initial X-ray, additional X-ray view,
CT of the chest and abdomen), these will be arranged by
the reporting radiographer at time of the CXR report.
Off-protocol radiographer reporting
Where the radiographer performing the CXR is con-
cerned about the appearance of the X-ray or by the clin-
ical condition of the patient, current practice at
Homerton University Hospital is for the CXR to be
reviewed by a reporting radiographer or a consultant
radiologist prior to the patient leaving the department.
This includes, for example, where the radiographer sus-
pects a pneumothorax, tuberculosis or cancer. If a radi-
ographer has concerns that the appearances of the CXR
is abnormal and a significant pathology may be present,
these patients will receive an immediate report, regard-
less of the reporting session allocation (immediate/
standard) so as not to negatively impact on patient man-
agement. All such occurrences will be identified, in-
cluded in the intention-to-treat principle, but we will
also carry out sensitivity analysis excluding them. In
view of randomisation, we expect the same rates of such
cases in intervention and control sessions.
Equivocal reporting radiographer reports
For cases where the reporting radiographer is unsure
with the findings, and/or clinical significance of the
CXR, they will be free to review the case with another
reporting radiographer and/or consultant radiologist.
This is in line with current best practice. This will in-
clude, for example, instances where previous cross-
sectional imaging is available for the patient, or where
there may be unfamiliar medical terminology on the
CXR request form. All occurrences will be recorded.
Consultant radiologist chest X-ray report
All CXRs will receive a consultant radiologist report
(general radiologists; experience range 2–21 years post
FRCR), blinded to the reporting radiographer CXR re-
port. Consultant radiologist reporting will occur at the
next session following the reporting radiographer report.
Interpretation will occur using PACS workstations and
the report will be entered into a secure database.
Comparison of radiographer and radiologist reports
The CXR reports generated by the reporting radiogra-
phers and consultant radiologists will be extracted,
anonymised for source of report (radiographer/radiologist)
and entered into a secure database using the unique study
identifier. A respiratory physician will compare the reports
for discrepancies, using a proforma with predefined cri-
teria for clinically significant abnormalities. Discrepancies
Woznitza et al. Trials  (2017) 18:521 Page 5 of 10
in observations, interpretations and recommendations will
be highlighted. These criteria have been previously vali-
dated [32]. Report comparison will occur within three
working days of the CXR examination.
Additional radiology investigations
All additional radiology investigations will be organised
by the radiology department following established de-
partmental operating procedures. These additional in-
vestigations would be performed as part of routine
clinical practice and will not require any additional
radiation exposure. The reporting radiographers, after
appropriate training, have been designated ‘non-medical
referrers’ according to IRMER 2000 legislation.
Repeat chest X-ray for suspected infection
According to British Thoracic Society (BTS) guidance
[33], patients who have a CXR that is suspicious for in-
fection require a follow-up CXR 6 weeks later following
antibiotic therapy to ensure resolution. The reporting
radiographer will arrange the follow-up CXR at the time
of the initial CXR report for the immediate reporting
arm, and the patient will be asked to re-attend the radi-
ology department in 6 weeks. This will be communi-
cated in the CXR report.
For patients who have a CXR suspicious for infection
in the standard care arm the recommendation for a
follow-up CXR in 6 weeks will be included in the report
conclusion. This will be requested by the general practi-
tioner, as is current practice.
CT of the chest
Patients who have an abnormal CXR suspicious for can-
cer will have a CT of the chest performed. The reporting
practitioner (reporting radiographer or consultant radi-
ologist) will arrange this following standard department
procedure. The CT scan forms part of routine clinical
management and, therefore, does not require any add-
itional radiation exposure. A consultant radiologist will
interpret all CTs.
The CT performed will be stratified based on the CXR
appearances and the likelihood of cancer. This will min-
imise radiation exposure, in line with best practice. For
patients with a CXR that is suspicious but not categor-
ical for lung cancer, a low-dose, unenhanced CT of the
chest will be performed. For patients who have a CXR
that shows a high likelihood of cancer, a CT of the chest
and abdomen with intravenously administered contrast
will be offered
Index diagnosis by thoracic radiologist
Chest X-rays that are found to have discordant reporting
radiographer and consultant radiologist reports at peer
review will have an index diagnosis. For cases that have
undergone a subsequent CT scan of the chest and abdo-
men, the CT report will constitute the index diagnosis.
CXR reports, either reporting radiographer or consultant
radiologist, will be deemed a true positive if CT confirms
the CXR diagnosis and a false positive if the CT is nor-
mal or another pathology is demonstrated. True positive
and true negative will be a consensus decision and cor-
roboration between the CT and clinical history between
a respiratory physician and a thoracic radiologist. As-
sessment of report accuracy will be made blinded to the
origin (reporting radiographer/consultant radiologist) of
the CXR report.
For cases that have not had a CT performed, an inde-
pendent expert thoracic consultant radiologist will con-
stitute the index diagnosis. The index radiologist will
feed back the diagnosis via a standardised proforma. All
available thoracic imaging (X-ray, CT) for the patient
will be sent via the Image Exchange Portal (IEP) to the
Royal Brompton Hospital. IEP is an established, secure
method of transferring radiology cases for external re-
view within the NHS. A thoracic consultant radiologist
will review the available imaging and provide the definite
diagnosis. CXR reports, both reporting radiographer and
consultant radiologist, will be deemed a true positive if
the thoracic radiologist confirms the CXR diagnosis and
a false positive if the thoracic radiologist interpretation
is normal or another pathology is demonstrated.
Statistical considerations
Sample size
For the primary endpoint in this pilot study, time to
treatment decision for lung cancers, if we expect an
11-day advance in time to first treatment decision,
with a standard deviation of 14 (previous audit data
suggest this degree of variation), 26 cancers in each
group will confer 80% power (two-sided testing, 5%
significance level), for the internal randomised com-
parison. We expect around 50 cancers per year in
Homerton University Hospital (HUH), so we will have
adequate power for this difference. A reduction in
time to diagnosis of 2 weeks was found to improve
mortality of lung cancer patients so this difference
could be clinically significant in the current pilot
study [34]. If we anticipate a 12-day, instead of an
11-day advance in diagnosis, we would only need 22
in each arm, 44 cancers in all, for 80% power. For
the external comparison, assuming that Newham Uni-
versity Hospital has a similar number of lung cancers
per year, therefore, we would have close to 90%
power for the same difference and standard deviation.
If we also compare times to diagnosis for all persons
referred to the pathway (lung cancer and non-lung
cancer diagnoses), previous data suggest an average of
18 days and a standard deviation of 14. If the
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intervention improves this by 7 days on average, with
a standard deviation of 15, we would need 73 subjects
in each group referred to the pathway to achieve 80%
power (two-sided testing, 5% significance level). Thus,
both the internal and external comparisons will be
adequately powered.
Data analysis
Times to diagnosis, treatment and other continuous
outcomes will be compared using simple t tests. Cat-
egorical outcomes, such as proportions of emergency
admissions, will be compared using Poisson regression.
Survival will be compared using proportional hazards
regression. Patient satisfaction will be recorded in
categorical outcomes, and will be compared using non-
parametric tests.
Patient satisfaction
Patients referred for a CXR from GP will be identified by
the radiology administration team, as is current practice.
Eligible patients will have a Patient Satisfaction Survey
posted to their home address, with a stamped self-
addressed return envelope. No patient-identifiable data
will be collected. Comparison will be made between
patients who received an immediate and routine CXR
report. The Patient Satisfaction Survey to be used has
been included as an Appendix.
Health economic assessment
Adaptation of a health economic model that exam-
ined the impact of radiographer CXR reporting on
the lung cancer pathway will be performed [35]. The
model for this project will map out the care path-
ways following standard reporting and immediate
reporting. It is assumed that differences in time to
treatment will affect severity and, hence, costs and
quality of life. Costs will be calculated from an NHS
perspective, covering a 1-year period, and include X-
ray reporting time, CXR cancer and non-cancer diag-
nostic accuracy, subsequent care costs, as well as
reading and supervision costs. The cost per case de-
tected will be reported. Quality-of-life scores will be
obtained from the academic literature for different
cancer stages and these will be used to generate
quality-adjusted life years (QALYs). One-way and
probabilistic sensitivity analyses will be conducted to
assess the impact on costs and cost-effectiveness of
changing parameters in the model. Due to the timing
of the intervention in relation to the lung cancer
pathway there may be no meaningful difference in
QALYs for the internal comparison. The reduction in
time to a non-lung cancer diagnosis may be a worth-
while improvement in quality of life.
Discussion
The current study will determine the effect of imme-
diate reporting of CXRs referred from GP, with im-
mediate CT where appropriate, on the time to
diagnosis of lung cancer. Although only one part of
the patient pathway, immediate GP CXR reporting
could positively impact lung cancer diagnosis and
outcomes in at least three ways: firstly, by providing
an immediate CXR report and initiating earlier fur-
ther investigation including CT, the time to diagnosis
will be shortened. There is debate within the aca-
demic literature as to the significance of this in terms
of improvements in early survival times, performance
status and reducing emergency admissions [34]. The
current study will examine this, both with internal
and external comparison. Secondly, the efficiency of
the service may be improved by reducing the number
of lung cancer pathway referrals through early
provision of an alternative diagnosis, which in turn
means less time for patient anxiety and distress.
Thirdly, the proposal may release consultant radiolo-
gist time that can instead be used to interpret more
complex cross-sectional imaging and support inter-
ventional procedures including lung biopsy. A reduc-
tion in average time to diagnosis for lung cancer will
help centres meet the ambitious target of 90% of lung
cancer patients definitively diagnosed within 28 days
by 2020 [14].
Diagnostic capacity is a significant barrier to improved
outcomes for cancer patients [14, 36], with prompt radi-
ology reports a particular issue across England [15, 18].
The limitations of the current study include the
fact that the intervention occurs only at a single
clinical site at which the diagnostic aspect of the
lung cancer pathway is already relatively streamlined.
This is addressed by external comparison with a
neighbouring hospital with similar patient character-
istics and a comparable number of lung cancers di-
agnosed annually.
Trial status
Study protocol version 1.5 of 2 May 2017. The study
will commence on 1 July 2017 and close on 30 June




Homerton University Hospital strives to offer effective,
patient-focused healthcare. In order to improve services
we would value your feedback on your experiences when
you recently attended the radiology department for a
chest X-ray. Please indicate your response to each ques-
tion by circling the appropriate answer.
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All answers are anonymous and confidential. If you
have any questions please contact Dr. Nick Woznitza,
radiographer, on 0208 510 7848.
Please return the completed survey in the stamped,
self-addressed envelope provided.
Q1 What is your gender?
Male
Female
Prefer not to answer














3. Gypsy or Irish Traveller
4. Any other White background, please describe
Mixed/Multiple ethnic groups
5. White and Black Caribbean
6. White and Black African
7. White and Asian















18. Any other ethnic group, please describe
Prefer not to answer
Q4 When were you told that the results of your
chest X-ray would be available?
Immediately – given by a radiographer
Immediately – to contact my GP
Next day – to contact my GP
Q5 Did you require any further tests?
Yes – done at the same time as the chest X-ray
Yes – done on another day after the chest X-ray
No
Q6 How do you feel about how you were told that
you needed further tests?
I did not need any further tests
It was done sensitively
It could have been done a bit more sensitively
It could have been done a lot more sensitively




Pleased that something was happening
Prefer not to say
Any comments?
Q8 Would you have liked to be contacted by your
own GP (Doctor) before the CT scan – even if this




Prefer not to say
Q9 How long did you wait for your results after
you had your CT scan?
Less than a week
1–2 weeks
More than 2 weeks
Can’t remember
Q10 If you had an appointment, was the booking
system flexible enough for you?




Q11 If you have any suggestions or comments
about the service you would like to make, please use
the space below
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 120 kb)
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